News update physiology, imaging, and Co-Reg

Prof Andrew Sharp qualified from Edinburgh Medical School in 1998 and is Professor of Cardiology at the University Hospital of Wales and Cardiff University in the U.K. He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the prestigious Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at Imperial College Hospitals in London. Prof Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and his research interests include intracoronary imaging and physiology. as well as the use of device-based treatments for hypertension and pulmonary embolism.

Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.

Dr Rasha Al-Lamee is an Interventional Cardiology Consultant at Imperial College Healthcare NHS Trust in London, UK. Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is the lead author of the primary publication in The Lancet. At Imperial College, she is actively involved in the development and recruitment for a number of multi-centre clinical trials. Dr Al- Lamee has over 40 peer-reviewed publications and has presented at international Cardiology conferences worldwide throughout her clinical career. She studied at the University of Oxford and University College London. She went onto complete her training as a junior doctor on the Barts and the London Medical rotation before being appointed as a Specialist Registrar on the North West London Cardiology rotation in 2006. Dr Al-Lamee has twelve years of Cardiology experience and completed three years of Interventional Fellowship training at Hammersmith Hospital in London. She also spent a year training as an Interventional Fellow under the supervision of Professor Antonio Colombo in Milan. She completed specialist training in Cardiology in 2013.